Chipscreen Biosciences, Ltd.

This phase 3 trial tested adding the drug tucidinostat to standard chemotherapy (R-CHOP) in 423 adults with a fast-growing type of lymphoma called double-expressor DLBCL. The goal was to see if the combination could delay the cancer from coming back or getting worse. Participants…

This study tested a combination of two drugs, tucidinostat and tislelizumab, as a first treatment for people with a certain type of advanced lung cancer (non-small cell lung cancer that is PD-L1 positive). The trial involved 118 adults who had not received prior treatment for the…